Bacteria bombs target stubborn tumors in new cancer combo trial

NCT ID NCT03435952

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times

Summary

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells from the inside, while pembrolizumab helps the immune system attack the cancer. The main goal is to find the safest dose of the bacteria and see if the combination can control the disease. Up to 18 participants will be treated at MD Anderson Cancer Center.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm breast cancer breast neoplasm cancer of unknown primary site central nervous system cancer digestive system cancer female reproductive organ cancer male reproductive organ cancer malignant endocrine neoplasm malignant urinary system neoplasm neoplasm respiratory system cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.